Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Chemistry

Biochemistry

Medicine

Cancer Oncology

Pathology

Show all topics

DOI

10.1016/s1470-2045(20)30445-9